GLP-1 weight loss timeline: what actually happens month by month

TLDR. The realistic GLP-1 weight-loss timeline: months 1 to 3 produce 3 to 7 percent body weight loss during titration; months 4 to 6 add another 5 to 8 percent on maintenance dose; months 7 to 12 add another 3 to 6 percent; months 13 to 24 add diminishing returns of 1 to 3 percent. Most patients land at 12 to 18 percent on Wegovy and 18 to 22 percent on Zepbound at month 18 to 24. Reddit screenshots showing dramatic month-1 losses are real but unrepresentative; STEP-1 trial data shows a more measured curve.

Patients starting a GLP-1 want to know two things: how fast will I lose weight, and when will I be done? The internet shows screenshots of 30-pound losses in 60 days. The trial data shows a much more measured curve. The reality, for most people, looks like the trial data.

This is the realistic month-by-month timeline drawn from STEP-1, SURMOUNT-1, and observational data we have read in published telehealth-program studies.

Month 1: side effects dominate

You start at 0.25 mg semaglutide or 2.5 mg tirzepatide. These are starter doses; they are not therapeutic for weight loss. They exist to acclimate your body before titrating up.

What you will notice:

• Reduced appetite, often dramatically. Some patients describe "food noise" turning off.
• Nausea, particularly in the 24 hours after injection. Take with a small bland meal.
• Constipation or, less often, diarrhea. Increase fiber and water before reaching for laxatives.
• Fatigue, especially during the first week.

Expected weight loss: 2-5 pounds. Some patients lose 8-10 pounds, but mostly because the appetite drop produces a calorie deficit larger than they realize. Don't chase that; aggressive early losses correlate with worse long-term retention.

Month 2-3: titration up, the real efficacy window opens

Standard protocol titrates monthly: 0.25 to 0.5 to 1.0 mg for semaglutide, 2.5 to 5 to 7.5 mg for tirzepatide. By month 3 you should be at 1.0 mg semaglutide or 7.5 mg tirzepatide.

Side effects often re-spike with each titration. Most patients can ride them out by month-end. If you cannot, holding at the previous dose for an extra month is acceptable and does not hurt your outcome long-term.

Expected cumulative weight loss by end of month 3: 6-10% of starting body weight, or roughly 12-22 pounds for a 200-pound starter. This is when patients tend to tell other people they are on a GLP-1, because the loss becomes visible.

Month 4-6: the steady-loss window

This is the most efficient phase of GLP-1 treatment. You are on a therapeutic dose, side effects are usually manageable and the appetite suppression is doing the work.

Expected cumulative weight loss by month 6: 12-15% of starting body weight on semaglutide, 15-20% on tirzepatide. A 200-pound starter is now at 165-176 pounds (semaglutide) or 160-170 pounds (tirzepatide).

Important: many patients hit their first plateau around month 5-6. This is normal. The plateau usually lasts 4-8 weeks before the curve resumes downward. See our plateau guide for what to actually do during a stall.

Month 7-12: the second half, with diminishing returns

The weight-loss rate slows. You are still losing, but maybe 0.5-1 pound per week instead of the 2-3 pounds per week of months 2-4. This is expected biology, not failure.

If you have not already, this is the dose-decision window: do you push to the maximum dose (2.4 mg semaglutide or 15 mg tirzepatide) or hold at a sub-maximum dose? The trial data showed similar weight-loss outcomes at lower doses for many patients, with fewer side effects. There is no medal for being on the highest dose.

Expected cumulative weight loss at month 12: 14-15% on semaglutide (matches STEP-1's 14.9% mean), 20-22% on tirzepatide (matches SURMOUNT-1's 22.5% mean).

If you are below these numbers, you are not failing. The trial averages include patients on maximum doses with intensive support. The cohort of mid-range responders is real and large.

Month 13-24: maintenance, with caveats

Most patients reach their nadir (lowest weight) somewhere between months 12 and 18. After that the body adapts and weight-loss slows or stops entirely.

Two decisions confront you here:

• Stay on the medication at the same dose: this is what most clinicians recommend. You maintain the loss; you may slowly add another 2-3% of weight loss over the next year. Expect to stay on the GLP-1 long-term, possibly forever. See our maintenance guide.
• Try to step down the dose: some patients do well at 1.0 mg semaglutide as a maintenance dose after reaching goal weight on 2.4 mg. The data on this is thin; the practice is increasingly common. Discuss with your prescriber.

What "off the medication" looks like

Most patients who stop GLP-1 entirely regain 60-70% of lost weight within 12 months. That is not a moral failure; it is the underlying biology of obesity reasserting itself. The medication treats the disease; stopping treatment is the same as stopping any other chronic-disease medication.

If you are taking the medication for a specific event (a wedding, a reunion), be honest with yourself: that motivation will not survive 12 months of post-stop regain. Plan to stay on the medication unless you have a strong specific reason to stop.

How to compress the timeline

You cannot. Aggressive caloric restriction on top of GLP-1 increases side effects and increases dropout. The drug is already doing the work; adding extra restriction is counterproductive.

What does help: high protein intake (1.0-1.2 g per kg of target body weight), resistance training 2-3 times a week to preserve muscle, adequate sleep and not skipping doses. Patients who do these four things land in the upper quartile of trial responders.

The fastest path to seeing the curve is to start. See our 30-second match quiz if you have not picked a program yet.

Frequently asked questions

How much will I lose in the first month of GLP-1?

Most patients lose 3 to 8 pounds in the first 4 weeks at the starting titration dose. Heavier patients sometimes see 8 to 12 pounds. The first-month curve is steep partly because of water-weight loss (the GLP-1 reduces appetite and meal size, which reduces sodium and water retention) and partly because compliance is highest in the first weeks.

When does the scale start moving meaningfully?

Around month 3, after you reach the first maintenance dose. By the end of month 3, most patients have lost 5 to 10 percent of starting body weight. Month 6 is typically 10 to 14 percent. Month 12 is typically 12 to 18 percent on Wegovy and 18 to 22 percent on Zepbound.

Why is my weight loss slower than my friend's?

Individual response varies. Genetic factors, sex (women lose slightly slower on average), starting BMI, sleep, stress, and adherence to dietary changes all matter. Trial data shows roughly 80 to 90 percent of patients achieve at least 5 percent loss by month 6 on maximum dose, but 10 to 15 percent are slow responders. Slow does not mean no response; the curve is just flatter.

What is realistic to expect at month 12?

On Wegovy 2.4 mg, 12 to 18 percent total weight loss (so 24 to 36 pounds for a starting weight of 200). On Zepbound 15 mg, 18 to 22 percent (36 to 44 pounds). Real-world averages run 2 to 4 percentage points below trial averages because adherence drops over time and not all patients reach the maximum dose.

Can I speed up the timeline?

Modestly, with strict adherence (no missed doses), 1.4 to 1.8 g/kg protein intake, resistance training twice weekly, and 7 to 9 hours of sleep. The biology of GLP-1 weight loss is dose-dependent and time-dependent; you cannot compress a 12-month curve into 4 months. Patients who try (extreme dieting, skipping titration) usually end up with worse side effects, not faster results.